ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: Moreover, the combination of alemtuzumab with fludarabine-cyclophosphamide-doxorubicin induced remission in 63% (58% CR) of ALK-negative PTCL patients treated in the front-line setting [80].